Oxidase activity of ceruloplasmin and some acute phase reactant and trace element concentrations in serum of patients with chronic lymphocytic leukemia

被引:12
|
作者
Gundogdu, M. [1 ]
Kaya, H.
Gulcin, I.
Erdem, F.
Cayir, K.
Keles, M.
Yilmaz, A.
机构
[1] Ataturk Univ, Sch Med, Dept Internal Med, TR-25240 Erzurum, Turkey
[2] Mustafa Kemal Univ, Dept Internal Med, Sch Med, Antakya, Turkey
[3] Dept Chem Sci & Art Fac, Erzurum, Turkey
[4] Nenehatun Obstetr & Gynecol Hosp, Dept Biochem, Erzurum, Turkey
关键词
D O I
10.1258/rsmsmj.52.1.24
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the present study, we aimed to investigate the parameters in serum of patients with chronic lymphocytic leukaemia (CLL) and correlate with the cancer stage. The serum concentrations of ceruloplasmin, a-1-acid glycoprotein, albuminumin, transferrin, copper, zinc, manganese, and ceruloplasmin oxidase activity were measured, and compared with those from a healthy control group. The serum from 34 patients with CLL were extracted before chemotherapy. Serum transferrin, allbuminumin and Zinc concentrations were lower in patients with CLL while serum a-1-acid glycoprotein, ceruloplasmin, copper concentrations, and ceruloplasmin oxidase activity were higher in CLL patients when compared with the control group. Although serum manganese concentration was lower in CLL groups than in the control group, the difference was not statistically significant. Serum transferrin concentration was lower in the early stage group compared with the advanced stage. Serum ceruloplasmin level positively correlated with serum ceruloplasmin oxidase activity in patients from the early stage group. Serum ceruloplasmin level positively correlated with serum ceruloplasmin oxidase activity in patients with advanced stage. In conclusion, increased serum ceruloplasmin oxidase activity, ceruloplasmin, a-1-acid glycoprotein, copper levels and decreased transferrin and albuminumin, unchanged manganese levels are associated with CLL and appear to be a consequence of the disease itself.
引用
收藏
页码:24 / 27
页数:4
相关论文
共 46 条
  • [21] DISTINCT PROTEIN WITH ALKALINE-PHOSPHATASE ACTIVITY IN SERUM OF PATIENTS WITH ACUTE LYMPHATIC LEUKEMIA (ALL), CHRONIC LYMPHATIC LEUKEMIA (CLL), AND INFECTIOUS-MONONUCLEOSIS (IM)
    MORAN, EM
    NEUMANN, H
    RUSSELL, RM
    ROSENBERG, IH
    JOURNAL OF CLINICAL INVESTIGATION, 1974, 53 (06): : A54 - A54
  • [22] Thymidylate synthase activity in leukocytes from patients with chronic myelocytic leukemia and acute lymphocytic leukemia and its inhibition by phenanthroindolizidine alkaloids pergularinine and tylophorinidine (vol 128, pg 183, 1998)
    Rao, KN
    Bhattacharya, RK
    Venkatachalam, SR
    CANCER LETTERS, 1998, 134 (01) : 119 - 119
  • [23] Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab
    Osterborg, Anders
    Ronn, Birgitte Biilmann
    Jewell, Roxanne C.
    Kipps, Thomas J.
    Mayer, Jiri
    Stilgenbauer, Stephan
    Williams, Cathy D.
    Hellmann, Andrzej
    Robak, Tadeusz
    Furman, Richard R.
    Hillmen, Peter
    Trneny, Marek
    Dyer, Martin J. S.
    Padmanabhan, Swami
    Piotrowska, Magdalena
    Kozak, Tomas
    Chan, Geoffrey
    Arning, Michael
    Losic, Nedjad
    Davis, Randy
    Wilms, Joris
    Russell, Charlotte A.
    Wierda, William G.
    BLOOD, 2009, 114 (22) : 1334 - 1334
  • [24] A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia
    Lin, Thomas S.
    Stock, Wendy
    Xu, Huiping
    Phelps, Mitch A.
    Lucas, Margaret S.
    Guster, Sara K.
    Briggs, Bruce R.
    Cheney, Carolyn
    Porcu, Pierluigi
    Flinn, Ian W.
    Grever, Michael R.
    Dalton, James T.
    Byrd, John C.
    LEUKEMIA & LYMPHOMA, 2009, 50 (12) : 1958 - 1963
  • [25] CHANGES IN SERUM COMPLEMENT ACTIVITY DURING ANTI-CD20 AND ANTI-CD52 MONOCLONAL ANTIBODY THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Stasilojc, Grzegorz
    Felberg, Anna
    Taszner, Michal
    Urban, Aleksandra
    Ma, Shuo
    Blom, Anna
    Lundin, Jeanette
    Osterborg, Anders
    Okroj, Marcin
    MOLECULAR IMMUNOLOGY, 2019, 114 : 415 - 415
  • [26] An Ongoing Phase 1 Study of ABT-263; Pharmacokineties, Safety and Anti-Tumor Activity in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).
    Roberts, Andrew W.
    Brown, Jennifer
    Seymour, John F.
    Wierda, William G.
    Kipps, Thomas J.
    Xiong, Hao
    Chiu, Yi-Lin
    Busman, Todd
    Knight, Raymond A.
    Enschede, Sari
    Krivoshik, Andrew
    Humerickhouse, Rod
    BLOOD, 2008, 112 (11) : 1089 - 1090
  • [27] A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.
    Jaglowski, Samantha Mary
    Jones, Jeffrey Alan
    Flynn, Joseph M.
    Andritsos, Leslie A.
    Maddocks, Kami J.
    Blum, Kristie A.
    Grever, Michael R.
    Geyer, Susan Michelle
    Woyach, Jennifer Ann
    Johnson, Amy J.
    Heerema, Nyla A.
    Molnar, Erin
    Stefanos, Mona
    Devlin, Susan
    Navarro, Tasheda
    James, Danelle Frances
    Lowe, Ann M.
    Hedrick, Eric
    Byrd, John C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [28] A Phase 1/2 Study Of The Safety and Activity Of Escalating Doses Of Lenalidomide Plus Rituximab For Patients With Refractory Or Relapsed Chronic Lymphocytic Leukemia (LLC-Lenar-08)
    Tomas, Jose Francisco
    Gonzalez, Marcos
    Giraldo, Pilar
    Terol, Ma Jose
    Simon, Jose Antonio Perez
    de Ona, Raquel
    BLOOD, 2013, 122 (21)
  • [29] A phase 1b/2 study evaluating activity and tolerability of the BTK inhibitor ibrutinib in combination with ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.
    Jaglowski, Samantha Mary
    Jones, Jeffrey Alan
    Flynn, Joseph M.
    Andritsos, Leslie A.
    Maddocks, Kami J.
    Woyach, Jennifer Ann
    Blum, Kristie A.
    Grever, Michael R.
    Geyer, Susan Michelle
    Heerema, Nyla A.
    Lozanski, Gerard
    Stefanos, Mona
    Hall, Nathan
    Nagar, Veena
    Munneke, Brian
    West, Jamie-Sue
    Neuenburg, Jutta
    James, Danelle Frances
    Johnson, Amy J.
    Byrd, John C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study
    Byrd, J. C.
    Blum, K. A.
    Burger, J. A.
    Coutre, S. E.
    Sharman, J. P.
    Furman, R. R.
    Flinn, I. W.
    Grant, B. W.
    Richards, D. A.
    Zhao, W.
    Heerema, N. A.
    Johnson, A. J.
    Izumi, R.
    Hamdy, A.
    O'Brien, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)